Wells Fargo analyst Derek Archila raised the firm’s price target on aTyr Pharma (ATYR) to $25 from $17 and keeps an Overweight rating on the shares. The firm is increasing its probability of success to 50% that efzo demonstrates statistical significance steroid reduction but also benefits on QOL in the upcoming Phase 3 read out for pulmonary sarcoidosis in early September. Wells would be a buyer ahead of data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
- Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
- aTyr Pharma announces interim analysis from Phase 2 EFZO-CONNECT
- aTyr Pharma management to meet with Piper Sandler
- Buy Rating for aTyr Pharma: Confidence in EFZO-FIT Phase 3 Trial Success